Information needed to decide about cardiovascular treatment in primary care

British Medical Journal

Volumn 314, Issue 7076, 1997, Pages 277-280

  Robson, John ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST BENEFIT ANALYSIS; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031027318     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.314.7076.277     Document Type: Article

References (47)

1. Kannel WB. Frainingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995;18:181-96.
2. Randall T, Muir J. Mant D. Choosing the preventive workload in general practice: practical application of the Coronary Prevention Group guidelines and Dundee coronary risk-disk. BMJ 1992;305:227-31.
3. Tunstall-Pedoe H. Value of the Dundee coronary risk-disk: a defence. BMJ 1992;305:231-2.
4. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
5. Drummond MF, Heyse J, Cook J, McGuire A. Selection of end points in economic evaluations of coronary-heart disease interventions. Med Decis Making 1993;13:184-90.
6. Sutherland HJ. Assessing patients preferences. Med Decis Making 1995;15:286-7.
7. Tunstall-Pedoe H. The Dundee coronary risk disk for management of change in risk factors. BMJ 1991;303:744-7.
8. Jackson R, Barham P, Bills J, Birch T, McLennan L, MacMahon S, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107-10.
9. Anderson KM, Wilson PW. Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
10. Shaper AG, Pocock SJ, Phillips AN, Walker M. A scoring system to identify men at high risk of a heart attack. Health Trends 1987;19:37-9.
11. Working Group of the Coronary Prevention Group and the British Heart Foundation. An action plan for preventing coronary heart disease in primary care. BMJ 1991;303:748-50.
12. Kannel WB. Office assessment of coronary candidates and risk factor insights from the Framingham study.J Hypertens Suppl 1991;9:S13-9.
13. Pyorala K, De Backer C, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31.
14. Wolf PA. D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham study. Stroke 1991;22:312-8.
15. Coppola WTG, Whincup PH, Papacosta O, Walker M, Ebrahim S. Scoring system to identify men at high risk of stroke: a strategy for general practice. Br J Gen Pract 1995;45:185-9.
16. Logan AG. Screening for hypertension in young and middle-aged adults. In: Canadian Task Force on the Periodic Health Examination, ed. The Canadian guide to clinical preventive health care. Canada: Minister of Supply and Services, 1994.
17. Medical Research Council Working Party. MRC trial of treatment of mild hypertension:principal results. BMJ 1985;291:97-104.
18. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995;346:1467-71.
19. Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
20. Ramsay LE, Haq IU,Jackson PR, Yeo WW. The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet 1996;348:1251-2.
21. Fletcher A. Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. J Hypertens 1991;9:193-8.
22. Pettiti DB. Meta-analysis, decision analysis and cost-effectiveness. Methods for quantitative synthesis in medicine. Oxford: Oxford University Press, 1994.
23. Richardson WS, Detsky AS. Users' guides to the medical literature, VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? JAMA 1995;273:1610-3.
24. Hux JE, Naylor C.D. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making 1995;15:152-7.
25. Cranney M, Walley T. Same information, different decisions: the influence of evidence on the management of hypertension in the elderly, Br J Gen Pract 1996;46:661-3.
26. Guyatt GH, Sackett DL, Cook DJ. Users' guide to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994;271:59-63.
27. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality; the importance of considering initial risk. BMJ 1993;306;1367-73.
28. Wennberg JE, Barry JM, Fowler FJ, Mulley A. Outcomes research, PORTs and health care reform. In: Warren SK, Mosteller F, eds. Doing more good than harm: the evaluation of health care interventions. New York: New York Academy of Sciences, 1993;52-62.
29. Robertson JAL. Policy goals for health and saftey: another view. Risk Analysis 1995;15:289-91.
30. McPherson K. The Cochrane lecture, The best and the enemy of the good: randomised controlled trials, uncertainly, and assessing the role of patient choice in medical decision making. J Epidemiol Community Health 1994;48:6-15.
31. Chalmers I. What do I want from health research and researchers when I am a patient? BMJ 1995;310:1315-8.
32. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995;15:369-90.
33. Russell LB. The role of prevention in health reform. N Engl J Med 1993;329:352-4.
34. Field K Thorogood M, Silagy C, Normand C, O'Neill C, Muir J. Strategies for reducing coronary risk factors in primary care: which is the most cost effective? BMJ 1995;310:1109-12.
35. Russell LB. Cost-effectiveness of antihypertensive treatment. General considerations. Hypertension 1989;13:1141-4.
36. Russell LB. Is prevention really better than cure? Washington DC: Brookings Institute, 1986.
37. Ubel PA, DeKay ML, Baron J. Asch DA. Cost effectiveness analysis in a setting of budget constraints. Is it equitable? N Engl J Med 1996;334:1174-7.
38. Lindholm L, Rosen M, Weinehall L, Asplund K. Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden. J Epidemiol Community Health 1996;50:190-5.
39. Swales JD, Ramsay LE, Coope JR, Pocock SJ, Robertson JIS, Sever PS, et al. Treating mild hypertension. Agreement from large trials. Report of the British Hypertension Society working party. BMJ 1989;298:694-8.
40. Beard K, Bulpitt C, Mascie-Tayor H, O'Malley K, Sever P, Webb S. Management of elderly patients with sustained hypertension. BMJ 1992;304:142-416.
41. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991;9:199-208.
42. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III-Analysis of data from trials of salt reduction. BMJ 1991;302:819-24.
43. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease,JAMA 1991;265:1145-51.
44. Jackson R, Beaglehole R. Evidence based management of dyslipidaemia. Lancet 1995;346:1441.
45. Shepherd J, Cobbe MS, Ford I, Isles C, Lorimer AR, Macfarlane PW, et al Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7.
46. Yusuf S, Anand S. Cost of prevention. The case of lipid lowering. Circulation 1996;93:1774-6.
47. Warren KS, Mosteller F, eds. Doing more good than harm: the evaluation of health care interventions. New York; New York Academy of Sciences, 1993.